Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital

LAUR Repository

Show simple item record

dc.contributor.author Kabbara, Wissam K.
dc.contributor.author Nawas, George T.
dc.contributor.author Ramadan, Wijdan H.
dc.date.accessioned 2016-10-03T08:10:14Z
dc.date.available 2016-10-03T08:10:14Z
dc.date.copyright 2015 en_US
dc.date.issued 2016-10-03
dc.identifier.issn 1178-6973 en_US
dc.identifier.uri http://hdl.handle.net/10725/4482
dc.description.abstract Background Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically and after culture results were available. Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. Results Patients from internal medicine and intensive care units comprised approximately 50% of the population in the study. The patients received imipenem/cilastatin mainly for urinary tract infections (27%) or for sepsis of an unknown focus (22%). The use of imipenem/cilastatin empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of the cases. There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients (13.8%) who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. Thirty-three patients (33%) were not dosed appropriately, 30 of whom had renal impairment and creatinine clearance fluctuations. Only one patient developed a seizure while on imipenem/cilastatin. Conclusion The prescription of imipenem/cilastatin at our setting was mostly appropriate to what is recommended in the guidelines and the literature, although a few cases could have been managed better. Dosage adjustment, however, was not as appropriate, mainly in patients who did not have a stable creatinine clearance. en_US
dc.language.iso en en_US
dc.title Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Infection and Drug Resistance en_US
dc.journal.volume 2015 en_US
dc.journal.issue 8 en_US
dc.article.pages 31-38 en_US
dc.keywords Imipenem en_US
dc.keywords Cilastatin en_US
dc.keywords Indication en_US
dc.keywords Dose en_US
dc.keywords Seizure en_US
dc.identifier.doi http://dx.doi.org/10.2147/IDR.S78633 en_US
dc.identifier.ctation Kabbara, W. K., Nawas, G. T., & Ramadan, W. H. (2015). evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital. Infection and drug resistance, 8, 31. en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378284/ en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account